Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426923 | 0.87 | SIGMAR1 (0.48) | LMNAHTR6ALDH1A1KDM4E | |
| SCHEMBL3426938 | 0.78 | HTR6 (0.59) | POLBLMNAHTR6ALDH1A1MC4R | |
| SCHEMBL3426339 | 0.78 | HTR6 (0.49) | HTR6ALDH1A1 | |
| SCHEMBL3425156 | 0.78 | KDM4E (0.42) | POLBHTR6KMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL3427636 | 0.77 | HTR6 (0.48) | HTR6ALDH1A1 | |
| SCHEMBL3428470 | 0.75 | KDM4E (0.49) | POLBHTR6KMT2AMEN1ALDH1A1 | |
| SCHEMBL3428459 | 0.71 | LMNA (0.47) | LMNAHTR6KMT2AALDH1A1KDM4E | |
| SCHEMBL3428016 | 0.70 | RAB9A (0.51) | HTR6KMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL3428675 | 0.69 | HTR6 (0.55) | POLBLMNAHTR6KMT2AMEN1 | |
| SCHEMBL3427576 | 0.69 | HTR6 (0.46) | HTR6ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781476-B2 | Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-24 | — | — | US | claimed |
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-06-21 | — | — | US | claimed |
| EP-1581538-B1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LTD (IN) | 2007-02-28 | — | — | EP | claimed |
| EP-1581538-A1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | Suven Life Sciences Limited (IN) | 2005-10-05 | — | — | EP | claimed |
| WO-2004055026-A1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-07-01 | — | — | WO | claimed |
| US-7781476-B2 | Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-24 | — | — | US | disclosed |
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-06-21 | — | — | US | disclosed |
| EP-1581538-B1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LTD (IN) | 2007-02-28 | — | — | EP | disclosed |
| EP-1581538-A1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | Suven Life Sciences Limited (IN) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004055026-A1 | TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | HTR3A, HTR3C, HTR3B | POLB 4814/4885LMNA 4601/4885HTR6 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.